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.2013.03.Abstract Background & Aim: Shivering is one of the serious complications during spinal anesthe-
sia. Mepreidine is considered the most common drug used for control of shivering. The aim of this
study is to detect if Magnesium sulfate can replace Mepreidine, in the prevention of shivering in
patients undergoing spinal anesthesia during knee arthroscopy.
Methods: The study included 50 patients scheduled for elective knee arthroscopy, aged 20–50 years
under spinal anesthesia. The patients were randomly divided into two equal groups. Patients in
Group (M) (n= 25) received single intravenous bolus dose of Meperidine 0.5 mg/kg while patients
in group (Mg) (n= 25) received intravenous (IV) MgSO4 in a dose of 50 mg/kg over 20 min fol-
lowed by 0.5 mg/kg/min both. The both test drugs were administered after establishment of spinal
anesthesia. The incidence and severity of shivering were recorded during the operation and in the
recovery room.
Results: Shivering occurred in 68% of patients in group (M) when compared to group (Mg) where
only 28% suffered from shivering. This difference in % was found to be statistically signiﬁcant.
Regarding the complications, local allergy signiﬁcantly occurred in group (M) in ﬁve patients when
compare to one patient in group (Mg). There was no signiﬁcant difference between group (M) and
group (Mg) regarding the body core temperature.
Conclusion: MgSO4 was found to be an effective way for the control shivering and it could replace
Meperidine in middle age patients under spinal anesthesia.
ª 2013 Egyptian Society of Anesthesiologists. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1111847.
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0021. Introduction
Shivering is an oscillatory involuntary muscular activity [1]
that may occur during knee arthroscopy, which is an unpleas-
ant sensation for all patients [2], surgeons, and anesthetist. It
interferes with the proper visualization of the ﬁeld which
resulting in ligament or vascular injury and results in inappro-
priate ECG and pulse oximeter monitoring as well [3].
The main value of shivering is to increase metabolic heat
production [4]. Also it increases the oxygen consumption fromosting by Elsevier B.V. Open access under CC BY-NC-ND license.
214 M. Elsonbaty et al.500% [5,6] up to 600% of the basal level [7], lactic acid, and
CO2 production with consequence increase in the cardiac out-
put and minute ventilation [8].
Shivering during knee arthroscopy occurs due to hypother-
mia which may be either due to irrigation of ﬂuid at room tem-
perature, or due to the effect of spinal or epidural anesthesia
[9] which are the common anesthetic techniques of choice in
knee arthroscopy. Regional anesthesia results in sympathetic
and somatic neural blockade on both vasomotor tone and
shivering below the level of the blockade [10].
Magnesium sulfate is found to be effective in management
of post-operative shivering after general anesthesia [11]. In the
present study, we compared the antishivering action between
Meperidine and Magnesium sulfate in middle age patients un-
der spinal anesthesia.
2. Materials and methods
This study was performed between January 2010 and June
2010 after approval of ethical committee of anesthesia depart-
ment (Faculty of Medicine Cairo University). The selected pa-
tients were scheduled for unilateral knee arthroscopy under
spinal anesthesia. Patients included in the study were ASA I
and II aged between 20 and 50 years, with no history of allergy
to Meperidine or Magnesium sulfate. Exclusion criteria in-
cluded patients with history of allergy, obese with body mass
index (BMI) h30 generalized infection or localized infection
at level of blockade, neurologic disease, coagulation disorder,
and patients refusing regional anesthesia.
This double-blinded randomized study included 50 patients
who were equally divided into two equal groups: Meperidine
group (M) and Magnesium sulfate group (Mg).
All routine investigations were done including complete
blood picture, coagulation proﬁle, liver function tests, kidney
function tests, blood grouping, and ECG, and written in-
formed consents were obtained.
Demographic data including age, weight, height, (BMI) and
ASA, also intra-operative data include (level of sensory block-
ade, total irrigation ﬂuid, and total surgical time) were recorded.
Preoperative hemodynamic data were recorded namely
mean blood pressure (MBP), heart rate (HR), arterial oxygen
saturation (SPO2), skin temperature (Ts), and tympanic tem-
perature (Tc).
No premedication was given to both groups. Peripheral
intravenous line was inserted and (15 mL/kg) Ringer’s lactate
solution warmed up to 37 C was given to all patients prior
to performance of spinal anesthesia, and all subsequent intra-
venous ﬂuids and irrigation ﬂuids given during the procedure
were also warmed.
Oxygen was administered via face mask (5 L/min). All
through the procedure and during the recovery time, the oper-
ating room temperature was maintained between 22 C and
25 C.
Midline Spinal anesthesia approach was performed to all
patients in the sitting position at the L3–L4 or L4–L5 inter-
spaces using 25-gauge Quincke needle using 2.5 mL hyperbaric
bupivacaine, 5 mg/mL.
After conﬁrming the establishment of the spinal anesthesia
level by pinprick, the patients were secured in the supine posi-
tion and wrapping the other limb in cotton towels and the
same standard tourniquet for knee was applied.In group M [1], patients received single bolus dose of
Meperidine 0.5 mg/kg diluted in 10 mL syringe intravenously
after establishment of spinal anesthesia.
In group Mg [2], patients received intravenous (IV) infusion
of MgSO4 50 mg/kg over 20 min followed by 0.5 mg/kg/min
infusion after establishment of spinal anesthesia.
The (MBP), (HR), (SPO2), (Ts), and (Tc) were measured
and recorded intermittently intra-operatively and in the recov-
ery room (every 15 min).
The incidence and severity of shivering were recorded dur-
ing the operation and in the recovery room. Shivering was
graded with a scale described by (Bedside Shivering Assess-
ment Score) (BSAS) as follows [12]:
1. None: no shivering noted on palpation of the masseter,
neck, or chest wall.
2. Mild: shivering localized to the neck and/or thorax only.
3. Moderate: shivering involves gross movement of the upper
extremities (in addition to neck and thorax).
4. Severe: shivering involves gross movements of the trunk
and upper and lower extremities.
Also any complications were recorded:
Hypotension was deﬁned as a decrease in the (MBP) to less
20% less than the baseline value, which was treated with 5–
10 mg of intravenous ephedrine.
Bradycardia was deﬁned as a decrease in HR less than 50 b/
min which was treated with 0.5 mg IV atropine.
2.1. Statistical analysis
The collected data were analyzed by Statistical Package for So-
cial Science (SPSS) version 16. Parametric data were expressed
as mean ± SD. The comparison the mean ± SD of two
groups was done using the paired and unpaired student’s t test.
Nonparametric data was expressed as number and percentage
of the total number of patients. Determining the extent of a
single observed series of proportions, difference from a theo-
retical or expected distribution was done using the Chi square
test and repeated-measures analysis of variance followed by
Bonferroni’s post hoc testing. P-value < 0.05 was considered
statistically signiﬁcant.
2.2. Outcome measures
The primary outcome measure was the dose of Magnesium
sulfate that prevented the shivering and at the same time did
not produce hypotension. The second outcome was the use
of Magnesium sulfate in avoiding complications secondary
to the use of Meperidine.3. Results
All the demographic data including age, sex, weight, height,
body mass index and ASA status (Table 1), operative data sur-
gical time, and total irrigation ﬂuid (Table 2) were comparable
between both groups.
As regards the level of sensory blockade in both groups,
minimal level was T10 and maximal level was T4 with no sig-
niﬁcant difference between the two groups.
Table 1 Demographic data.
Variable each group (n= 25) Mean ± std. deviation P value
Age Group (M) 38.36 ± 8.36 0.60
Group (Mg) 39.64 ± 8.78
Sex (M/F) Group (M) 10/15 0.39
Group (Mg) 12/13
ASA (/ll) Group (M) 11/14
Group (Mg) 15/10
Weight (kg) Group (M) 73.36 ± 10.19 0.77
Group (Mg) 78.6 ± 10.31
Height (cm) Group (M) 175.36 ± 13.56 0.105
Group (Mg) 180.64 ± 8.42556
BMI Group (M) 24.18 ± 4.38 0.935
Group (Mg) 24.27 ± 4.10
Data were express as mean (±SD), P value < 0.05 is considered signiﬁcant. Group (M) =Meperidine group. Group (Mg) =Magnesium
sulfate group, BMI = body mass index.
Table 2 Operative data.
Group (M) n= 25 Group (Mg) n= 25 P value
Anesthesia time (min) 84.2(13.81) 86.52(15.894) 0.57
Surgical time (min) 68.08(12.524) 71.4(14.108) 0.38
Total irrigation ﬂuid (L) 2.7(0.9165) 3.18(1.008) 0.09
Data are expressed as mean (±SD), P value < 0.05 is considered signiﬁcant. Group (M) =Meperidine group. Group (Mg) =Magnesium
sulfate group.
Figure 1 Core temperature change over time in both groups,
Tc0 = basal core temperature, Tc1 = core temperature 1,
Tc2 = core temperature 2, Tc3 = core temperature 3, Tc4 = core
temperature 4 (interval 15 min).
Table 3 Shivering score among groups.
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with an insigniﬁcant lower values in group (Mg) when com-
pared to group (M) in Fig. 1.
Shivering was observed in seven patients (28%) in Mag-
nesium sulfate group and 17 patients (68%) in Meperidine
group with a statistically difference (p< 0.05) as was
Table 3.Concerning the associated local allergy, it was observed in
ﬁve patients in group (M) and only in one patient in group
(Mg). This difference was found to be statistically signiﬁcant
(Table 4).
On the other hand, no statistically signiﬁcant difference was
observed between both groups with respect to the incidence of
other complications.
4. Discussion
Shivering under regional anesthesia occurs in about 56.7%
[13], mainly due to impairment of afferent thermal input [10]
as a thermoregulatory response to hypothermia.
Subsequent complications included hypoxia, cardiac com-
plications as tachycardia, increased intracranial, and intraocu-
lar pressure. Therefore, treatment of shivering is crucial. Many
physical methods used to control shivering include increased
ambient room temperature, radiant heaters, warm IV ﬂuid
and wrapping the nonsurgical area in cotton towels [14], but
all these methods proved not to be enough to prevent shiver-
Table 4 Incidence of adverse side effect.
Group (M) n= 25 Group (Mg) n= 25 P value
Itching 2 0 0.149
Hypotension 2 1 0.557
Local allergy 5 1 0.018*
Generalized allergy 0 0
P value < 0.05 is considered signiﬁcance.
* Signiﬁcant difference.
216 M. Elsonbaty et al.ing. Many pharmacological methods have been tested in
reducing perioperative hypothermia [13] and suppressing
post-anesthetic shivering; however, none of these have received
universal acceptance.
Meperidine (a phenylpiperidine compound) has been dis-
cussed to be an effective opioid agent for management of
shivering and is considered the master drug used for manage-
ment of perioperative shivering. The antishivering action of
Meperidine is unclear. It is found to decline the threshold of
shivering through multimodal mechanisms, j-opioid receptors,
a2B-adrenoreceptor agonist, and NMDA receptor antagonism
[15–17].
Kurz et al. compared the antishivering characteristic of
Meperidine with low dose naloxone blocking l receptor and
high dose naloxone blocking both l and j receptor; they found
that the Meperidine with low dose naloxone was not affected,
but the antishivering activity was decreased when high dose
was used which indicates that the antishivering effect of
Meperidine is partially mediated through j-opioid receptors
[18] and not through the l-receptor that why it is more effec-
tive than other opioid agents as alfentanil as antishivering
agent [19]. However, Sajedi and Nazemroaya [20] found that
there were no differences in efﬁcacy to control post-operative
shivering among Meperidine, alfentanil, sufentanil, fentanyl,
and tramadol in management of shivering grade and V, and
they concluded that this group of drugs may have other anti-
shivering mechanism rather than their opioid receptors action.
In the present study, it was observed that ﬁve patients in the
Meperidine group suffered from local redness. This was consis-
tent with the study done by Blunk et al. [21]. They observe that
in the spite of using small dose of Meperidine, local itching and
redness around the site of injection and rarely ﬂushing, severe
hypotension, and tachycardia as a result of mast cell activation
and histamine release may attenuate its use as an antishivering
agent. They requested the need to ﬁnd another agent with less
side effects especially during regional anesthesia [21].
Concerning the antishivering effect, we observe that although
Meperidine is effective in management of perioperative shiver-
ing, Magnesium sulfate was founded to be signiﬁcantly more
effective.
Magnesium sulfate is a noncompetitive antagonist of
N-methyl-D-aspartate (NMDA) receptors, and also, it is natu-
rally occurring calcium antagonist [22]. It was found to be
effective in prevention of shivering [11]. The exact mechanism
by which it prevents shivering is not clear. It may be due to
blocking of NMDA receptors leading to a decrease in norepi-
nephrine, and 5-HT and both have role in thermoregulatory
control. Magnesium sulfate is an attractive choice for shivering
control because hypomagnesemia commonly is observed dur-
ing induced hypothermia [23].Another action of MgSO4 is modulation of NMDA recep-
tors at the level of dorsal horn of the spinal cord which affects
the ascending nociceptive transmission [24].
Although Kizilirmak et al. used 30 mg/kg IV bolus of
Magnesium sulfate which is considered smaller than that
we used, they found it enough to stop post-operative shiver-
ing after general anesthesia. This may be due to its use in
the post-operative period when there is no more hypother-
mia [11]. Gozdemir et al. [25] studied the effect of
Magnesium sulfate on Perioperative shivering during spinal
anesthesia, and they found that Magnesium sulfate is con-
sidered an excellent agent with less side effect than Meperi-
dine. In our study, we used smaller dose of Magnesium
sulfate than that used in Gozdemir et al. study and it was
found to be effective.
Using of this, dose of Magnesium sulfate was not associ-
ated with any hemodynamic unstability as higher dose would
cause vasodilatation and subsequent hypotension.
5. Conclusion
It was found that Magnesium sulfate is signiﬁcantly effective
than Meperidine in management of shivering during spinal
anesthesia with lower incidence of side effect.
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